Jeffrey Crowley

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 790 citations · Full text

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams et al. · New England Journal of Medicine · 2016 · 741 citations

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich, Melinda Gooderham, Diamant Thaçi et al. · The Lancet · 2019 · 286 citations

Rheumatology, Autoimmune Disease, Active-comparator-controlled Phase 3 +8

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases · 2016 · 275 citations · Full text

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology · 2017 · 182 citations · Full text